| 61.26 -1.66 (-2.64%) | 06-29 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 75.13 |
1-year : | 81.15 |
| Resists | First : | 64.33 |
Second : | 69.48 |
| Pivot price | 62.71  |
|||
| Supports | First : | 56 |
Second : | 46.59 |
| MAs | MA(5) : | 64.36 |
MA(20) : | 61.77 |
| MA(100) : | 65.7 |
MA(250) : | 64.36 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 39.5 |
D(3) : | 58 |
| RSI | RSI(14): 46 |
|||
| 52-week | High : | 85.25 | Low : | 38.5 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ TARS ] has closed above bottom band by 31.0%. Bollinger Bands are 30.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 62.98 - 63.36 | 63.36 - 63.64 |
| Low: | 59.87 - 60.36 | 60.36 - 60.73 |
| Close: | 60.61 - 61.34 | 61.34 - 61.88 |
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Mon, 29 Jun 2026
Tarsus Pharmaceuticals (TARS) director receives RSU and stock option grants - Stock Titan
Mon, 29 Jun 2026
Tarsus Pharmaceuticals (TARS) grants director RSUs and stock options - Stock Titan
Mon, 29 Jun 2026
Tarsus (TARS) director Wendy Yarno receives RSU and option grants as board pay - Stock Titan
Mon, 29 Jun 2026
Tarsus (TARS) director William J. Link granted options and RSUs - Stock Titan
Fri, 26 Jun 2026
Tarsus Pharmaceuticals Inc (TARS) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Thu, 25 Jun 2026
Tarsus Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:TARS) - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 43 (M) |
| Shares Float | 32 (M) |
| Held by Insiders | 3 (%) |
| Held by Institutions | 109.8 (%) |
| Shares Short | 4,980 (K) |
| Shares Short P.Month | 4,910 (K) |
| EPS | -1.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.06 |
| Profit Margin | -9.1 % |
| Operating Margin | -3.8 % |
| Return on Assets (ttm) | -5.9 % |
| Return on Equity (ttm) | -14 % |
| Qtrly Rev. Growth | 106.9 % |
| Gross Profit (p.s.) | 9.94 |
| Sales Per Share | 12.43 |
| EBITDA (p.s.) | -1.14 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -16 (M) |
| Levered Free Cash Flow | -21 (M) |
| PE Ratio | -55.19 |
| PEG Ratio | 0 |
| Price to Book value | 7.59 |
| Price to Sales | 4.92 |
| Price to Cash Flow | -160.21 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|